Introduction
Established practice of immunotherapy of cancer
Modality | Principle |
---|---|
Hematopoietic stem cell transplantion (e.g., leukemia and myeloma) | 1. Reset the immune system |
2. Allo-antigen response (graft versus tumor effect) | |
Antibody (e.g., retuximab, trastuzumab) | 1. Eliminate cancer cells |
2. Block key signaling pathways | |
Cytokines (e.g., type I interferon, interleukin-2) | Boost both innate and adaptive immunity |
Dendritic cells (e.g., Sip-T for prostate cancer) | Enhance tumor-specific T cell priming |
T cell checkpoint blockade (e.g., Ipilumimab for melanoma) | Block/reverse immune tolerance |
Microbes (e.g., BCG for the transitional bladder cancer) | Enhance innate and adaptive immunity |
What is hot in cancer immunotherapy in 2013?
Key unanswered questions in cancer immunology
Theme | Research question |
---|---|
Immune recognition of cancer
| What are characteristics of antigens critical for immune recognition of cancer cells? Do these antigens exist for all cancers? |
Fate determination of tumor immunity
| Tumors are not bacteria, not viruses, and not parasites. How do differences in antigen presentation and innate immunity signals impact the ability to initiate and mediate effective anti-tumor immunity? |
Mechanism of immune evasion
| Are immune evasion and oncogenesis closely coupled? What is the molecular definition of oncoinflammation in the tumor environment and its impact on cancer immunity? |
Immunotherapy
| It is time to redefine the goals of conventional therapy to convert non-immunogenic signals to immunogenic ones. What is the best strategy to combine immunotherapy with radiation therapy, chemotherapy or targeted therapy? More innovative immunotherapeutic strategies are needed including novel targets (e.g., cancer stem cells), novel sources of antigens (subdominant antigens), novel adjuvants, novel cytokines and new ways to reset the immune system from tolerogenic status to immunogenic one. |